Stage III Intrahepatic Cholangiocarcinoma

specific

Stage III includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum or involving the local extra hepatic structures by direct invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 7th Ed.)

Centers

Active Trials

—

Cancer Funding

Top Centers for Stage III Intrahepatic Cholangiocarcinoma(18)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Active Trials	Cancer Funding	Score
1	The University of Texas MD Anderson Cancer CenterHouston, TX NCI Comprehensive	—	—	52.8
2	The University of Chicago Medicine Comprehensive Cancer CenterChicago, IL NCI Comprehensive	—	—	52.8
3	Winship Cancer InstituteAtlanta, GA NCI Comprehensive	—	—	52.8
4	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive	—	—	52.8
5	Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive	—	—	52.8
6	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive	—	—	52.8
7	Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, IN NCI Comprehensive	—	—	52.8
8	Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical	—	—	52.8
9	Dartmouth Cancer CenterLebanon, NH NCI Comprehensive	—	—	52.8
10	University of Illinois Cancer CenterChicago, IL	—	—	52.8
11	University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical	—	—	52.8
12	University of New Mexico Comprehensive Cancer CenterAlbuquerque, NM NCI Comprehensive	—	—	52.8
13	UAMS Winthrop P. Rockefeller Cancer InstituteLittle Rock, AR	—	—	52.8
14	Boston University Cancer CenterBoston, MA	—	—	52.8
15	Cancer Center at IllinoisUrbana, IL	—	—	52.8
16	University of Cincinnati Cancer CenterCincinnati, OH	—	—	52.8
17	Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL	—	—	52.8
18	The University of Vermont Cancer CenterBurlington, VT	—	—	52.8

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →